¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Large-Conductance Calcium-Activated Potassium Channel alpha Subunits"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • voltage gated channel
    Àü¾ÐÀÛµ¿Åë·Î
  • alpha emitter
    ¾ËÆÄ¹æÃâü
  • alpha error
    ¾ËÆÄ¿À·ù, Á¦1Çü¿À·ù
  • alpha granule
    ¾ËÆÄ°ú¸³
  • alpha hemolysis
    ¾ËÆÄ¿ëÇ÷
  • alpha motor neuron
    ¾ËÆÄ¿îµ¿½Å°æ¼¼Æ÷
  • alpha ray
    ¾ËÆÄ¼±
  • alpha wave
    ¾ËÆÄÆÄ
  • alpha-adrenergics
    ¾ËÆÄ¾Æµå·¹³¯¸°¼º¾à
  • alpha-chymotrypsin
    ¾ËÆÄŰ¸ðÆ®¸³½Å
  • alpha-fetoprotein
    ¾ËÆÄžƴܹéÁú
  • alpha-lipoproteinemia
    ¾ËÆÄÁöÁú´Ü¹éÇ÷Áõ
  • interferon alpha
    ÀÎÅÍÆä·Ð¾ËÆÄ
  • interferon alpha-2b
    ÀÎÅÍÆä·Ð¾ËÆÄ-2b
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • channel block
    Åë·ÎÂ÷´Ü
  • channel
    Åë·Î
  • cation channel
    ¾çÀÌ¿ÂÅë·Î
  • collateral channel
    °çÅë·Î
  • collector channel
    Áý°á°ü, Áý°á·Î
  • fast channel
    ±Þ¼ÓÅë·Î
  • gated channel
    °ü¹®Åë·Î
  • sodium channel
    ³ªÆ®·ýÅë·Î
  • transmembrane channel
    ¸·Åë·Î
  • voltage gated channel
    Àü¾ÐÀÛµ¿Åë·Î
  • parallel channel sign
    ÆòÇà°ü¡ÈÄ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • potassium losing nephritis
    Ä®·ý»ó½Ç¼º ½Å¿°.
  • potassium losing nephritis
    Ä®·ý»ó½Ç¼º ½Å¿°(¡­ßÃã÷àõ ãìæú)
  • potassium oxalate
    ¼ö»êÄ®·ý
  • potassium secretion
    Ä®·ýºÐºñ
  • potassium sparing diuretic
    Æ÷Ÿ½·<Ä®·ý>-º¸Á¸(¼º) ÀÌ´¢Á¦.
  • potassium urate crystal
    ¿ä»êÄ®·ý°áÁ¤
  • 17-alpha-hydroxycorticosteroid
    17-¾ËÆÄ-È÷µå·Ï½ÃÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
  • 17-alpha-hydroxyprogesterone
    17-¾ËÆÄ-È÷µå·Ï½ÃÇÁ·Î°Ô½ºÅ×·Ð
  • alpha behavior
    ¾ËÆÄÇàÀ§
  • alpha blocking
    ¾ËÆÄÂ÷´Ü
  • alpha cell
    ¾ËÆÄ¼¼Æ÷
  • alpha cell
    ¾ËÆÄ¼¼Æ÷(¡­á¬øà)
  • alpha cell glucagon cell
    ¾ËÆÄ¼¼Æ÷ ±Û·çÄ«°ï¼¼Æ÷
  • alpha cell tumor
    ¾ËÆÄ ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • alpha chain disease
    ¾ËÆÄ¼âº´(¡­áðÜ»).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • potassium losing nephritis
    Ä®·ý»ó½Ç¼º ½Å¿°.
  • potassium losing nephritis
    Ä®·ý»ó½Ç¼º ½Å¿°(¡­ßÃã÷àõ ãìæú)
  • potassium oxalate
    ¼ö»êÄ®·ý
  • potassium secretion
    Ä®·ýºÐºñ
  • potassium sparing diuretic
    Æ÷Ÿ½·<Ä®·ý>-º¸Á¸(¼º) ÀÌ´¢Á¦.
  • potassium urate crystal
    ¿ä»êÄ®·ý°áÁ¤
  • sodium-potassium pump
  • acetylcholine channel
    ¾Æ¼¼Æ¿Äݸ° Åë·Î
  • calcium channel
    Ä®½·Åë·Î( -÷×ÖØ).
  • calcium channel
    Ä®½· Åë·Î(÷×ÖØ)
  • calcium channel antagonist,blocker
    Ä®½·Åë·Î ±æÇ×Á¦( -÷×ÖØ ÑÏù÷ð¥),Â÷´ÜÁ¦(ó´Ó¨ð¥).
  • cation channel
    ¾ç(åÕ)À̿ Åë·Î(÷×ÖØ)
  • channel
    Åë·Î.
  • channel
    Åë·Î(÷×ÖØ)
  • channel block
    Åë·ÎÂ÷´Ü
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • alpha tocopherol
    ¾ËÆÄÅäÄÚÆä·Ñ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AOA American Osteopathic Association; Administration on Aging; Alpha Omega Alpha Honor Society; American...
PAL pathology laboratory; peptidyl-alpha-hydroxyglycine alpha-amidating lysine phase alteration plane; p...
ROC Receptor Operated Channel
VSC Voltage Sensitive Channel
Ca2+-blocker calcium channel blocker
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LPD Low Potassium Dextran
PK Potassium
KTP Potassium-titanyl-phosphate
Na-K ATPase and potassium activated adenosine triphosphatase
SSKI potassium iodide
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • sear channel teeth
    ½Ã¾î ä³Î µµÄ¡
    ºñÇØºÎÇÐÀû ÇüÅÂÀÇ µµÄ¡·Î¼­ ±³ÇÕ¸éÀº »ó, ÇÏ¾Ç ¸ðµÎ °ÅÀÇ ÆòźÇϰí ÇϾǿ¡¼­´Â ±Ù¿ø½ÉÀûÀ¸·Î ´Þ¸®´Â °¡´Â µ¹±â°¡ ÀÖÀ¸¸ç »ó¾Ç¿¡´Â À̰ÍÀÌ µé¾î°¡´Â ¾èÀº ±¸°¡ ÀÖ´Ù.
  • A alpha
    A ¾ËÆÄ, A ¾ËÆÄ ½Å°æ ¼¶À¯
  • A alpha primary afferent
    A ¾ËÆÄ ÀÏÂ÷ ±¸½É ½Å°æ
    ±Ù¹æÃß ³»ÀÇ ±Ù ¼¶À¯¿¡ Á¸ÀçÇÏ´Â °¨°¢½Å°æÀÇ Çϳª·Î ¥°a °¨°¢ ½Å°æÀ̶ó°íµµ ÇÑ´Ù. Á÷°æÀº 22§­, Àüµµ ¼Óµµ´Â 120§½ÀÌ´Ù.
  • A-alpha mechanoreceptor
    A ¾ËÆÄ ±â°è ¼ö¿ë±â
    ±Ù ¹æÃß¿Í °ñÁö °Ç ±â°ü¿¡ Á¸ÀçÇÑ´Ù.
  • alpha
    ¥á
    chain
  • alpha 1-adrenergic blocker
    ¾ËÆÄ 1-¾Æµå·¹³¯¸°¼º Â÷´Ü
  • alpha 2 agonist clonidine
    ¾ËÆÄ 2 ÀÛµ¿ Ŭ·Î´Ïµò
  • alpha 2 binding
    ¾ËÆÄ 2 °áÇÕ
  • alpha adrenergic antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸° ±æÇ×Á¦
  • alpha amylose
    ¾ËÆÄ-¾Æ¹Ð·Î½º
    °ÅÀÇ ¾Æ¹Ð·Î½ºÀÎ ÀüºÐÀÇ ÁÖ¼ººÐÀ¸·Î¼­, ±Û·çÄÚ½º°¡ a-1,4 °áÇÕÀ¸·Î Á÷¼â»ó °áÇÕÇÑ °Í.
  • alpha efferent motor neuron
    ¾ËÆÄ ¿ø½É ¿îµ¿ ´º¿ì·±, ¾ËÆÄ ¿ø½É¼º ¿îµ¿ ´º·±
  • alpha fiber
    ¾ËÆÄ ¼¶À¯, ¾ËÆÄ ½Å°æ¼¶À¯
  • alpha hemolysis
    ¾ËÆÄ ¿ëÇ÷
  • alpha motorneuron
    ¾ËÆÄ ¿îµ¿ ´º¿ì·Ð
  • alpha ray
    ¾ËÆÄ ¼±
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
5 alpha-androstane-3 beta,17 beta-diol 6 alpha-hydroxylase <enzyme> Requires NADPH, found in rat prostatic microsomes
Registry number: EC 1.14.13.-
Synonym: artdl 6 alpha-hydroxylase
(26 Jun 1999)
5 alpha-androstane 3 beta,17 beta-diol 7 alpha-hydroxylase <enzyme> Requires NADPH, found in rat prostate microsomes
Registry number: EC 1.14.13.-
Synonym: artdl 7 alpha-hydroxylase
(26 Jun 1999)
5 alpha-dihydroprogesterone 3 alpha-hydroxysteroid oxidoreductase <enzyme> Catalyses conversion of 5 alpha-dihydroprogesterone to 3 alpha -hydroxy-5 alpha-pregnane-20-one
Registry number: EC 1.1.1.-
Synonym: 5-dp-3 alpha-hso, NADPH-5 alpha-dihydroprogesterone 3 alpha-hydroxysteroid oxidoreductase, alpha-hsor
(26 Jun 1999)
5 beta-cholestane-3 alpha,7 alpha-diol 26-hydroxylase <enzyme> Nadp-dependent
Registry number: EC 1.14.13.-
(26 Jun 1999)
7 alpha-hydroxy-4-cholesten-3-one-12 alpha monooxygenase <enzyme> Liver microsomal enzyme active in conversion of cholesterol to cholic acid; introduces a 12 alpha-hydroxyl group into the steroid nucleus of cholesterol
Registry number: EC 1.14.99.-
Synonym: 7-hco-monooxygenase, hco 12 alpha-hydroxylase
(26 Jun 1999)
calcium channel <physiology> A membrane channel that is specific for calcium. It is a voltage-dependent cell membrane glycoproteins selectively permeable to calcium ions. They are categorised as l, t, n, or p types based on the activation and inactivation kinetics, ion specificity, and sensitivity to drugs and toxins.
(12 May 2002)
calcium channel agonist <pharmacology> Agents that increase calcium influx into calcium channels of excitable tissues.
This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture.
(12 Dec 1998)
calcium channel antagonist <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
calcium channel-blocker <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
gated ion channel <physiology> Transmembrane proteins of excitable cells, that allow a flux of ions to pass only under defined circumstances. Channels may be either voltage gated, such as the sodium channel of neurons or ligand gated such as the acetylcholine receptor of cholinergic synapses. Channels tend to be relatively ion specific and allow fluxes of typically 1000 ions to pass in around 1ms, they are thus much faster at moving ions across a membrane than transport ATPases.
(05 May 1997)
voltage-gated channel A class of ion channel's that open and close in response to change in the electrical potential across the plasma membrane of the cell; voltage-gated Na+ c.'s are important for conducting action potential along nerve cell processes.
(05 Mar 2000)
voltage gated ion channel <physiology> A transmembrane ion channel whose permeability to ions is extremely sensitive to the transmembrane potential difference. These channels are essential for neuronal signal transmission and for intracellular signal transduction.
See: sodium channel.
(18 Nov 1997)
channel A furrow, gutter, or groovelike passageway.
See: canal.
Origin: L. Canalis
(05 Mar 2000)
channel forming ionophore <chemistry> An ionophore that makes an amphipathic pore with hydrophobic exterior and hydrophilic interior. most known types are cation selective.
(18 Nov 1997)
channel gating <physiology> Small currents in the membrane just prior to the increase in ionic permeability, due to the movement of charged particles within the membrane.
So called because they open the gates for current flow through ion channels.
(20 Mar 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • potassium nitrate
    Áú»êÄ®·ý
  • potassium sulfate
    Ȳ»êÄ®·ý
  • channel
    ¼ö·Î
  • Channel Islands
    ÇØÇùÁ¦µµ(ÇÁ¶û½º ºÏ¼­ºÎÀÇ ¿µ·ÉÀÇ ¼¶)
  • English Channel
    ¿µ±¹ ÇØÇù
  • North Channel
    ³ë½º ÇØÇùÄÚÆ²·£µå¿Í ºÏ¾ÆÀÏ·£µå »çÀÌ)
  • channel
    ÇöÃø°è·ùÆÇ(µÀ´ëÀÇ ¹öÆÀÁÙÀ» ¸É)
  • channel
    °­¹Ù´Ú;ÇÏ»ó;À¯»ó;¼ö·Î;°¡Ç×¼ö·Î;¿îÇÏ;ÇØÇù;(º¸µµ,¹«¿ª µîÀÇ)°æ·Î;·çÆ®;°èÅë;(Á¤½Ä)Àü´Þ ·çÆ®;(¿Õº¹ µîÀÇ)°æ·Î;(¶óµð¿À.ÅÚ·¹ºñÀü µîÀÇ)ä³Î;(ÇÒ´çµÈ)Á֯ļö´ë;(»ç»ó.Çൿ µîÀÇ)¹æÇâ;¹æÄ§;(Ȱµ¿ÀÇ)ºÐ¾ß;(µµ·ÎÀÇ)µµ¶û;Ãø±¸;¾Ï°Å;¼Ò°ü;µµ°ü;(¹®Áö¹æ µîÀÇ Àå½ÄȨ,(ÀϹÝÀûÀ¸·Î) °¡
  • channel iron (bar)
    Ȩ¼è(UÀÚ ¸ð¾çÀÇ ¼â.¸ø) a
  • channel lease
    ä³Î¸®½º(À¯¼± TVÀÇ ºó ä³ÎÀÇ ´ë¿©(Â÷¿ë))
  • channel separation
    ä³ÎºÐ¸®
  • channel(l)ed
    ȨÀÌ ÀÖ´Â
  • cross-channel
    ÇØÇùȾ´ÜÀÇ;ÇØÇùÀÇ ¸ÂÀº Æí ÂÊÀÇ(ƯÈ÷ ¿µ±¹ ÇØÇùÀÇ)
  • idiot channel
    ¹Î°£ ÅÚ·¹ºñÁ¯ ¹æ¼Û
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á